Printer Friendly

Teleflex Starts Phase I Clinical Study of RePlas Freeze-Dried Plasma.

M2 PHARMA-May 16, 2017-Teleflex Starts Phase I Clinical Study of RePlas Freeze-Dried Plasma

(C)2017 M2 COMMUNICATIONS

- US-based medical technology company Teleflex Inc. (NYSE: TFX) has launched the Phase I clinical study of RePlas, a lyophilized fresh frozen plasma product being developed in collaboration with the US Army Medical Materiel Development Activity (USAMMDA), the company said.

The product was originally developed by biologic scientists at Vascular Solutions, Inc., which was acquired by Teleflex in February.

RePlas Freeze-Dried Plasma was administered to the first patient as part of a 24-patient Phase I study (FDP-1) being conducted at the Hoxworth Blood Center at the University of Cincinnati.

In this first stage of the clinical development program, healthy volunteers receive increased doses of autologous freeze-dried plasma their own blood plasma that has been processed using the proprietary lyophilization (freeze drying) and packaging techniques, to assess safety and tolerability.

The early administration of plasma has an important role in reducing trauma mortality from uncontrolled bleeding (hemorrhage).

Therefore, USAMMDA has made the development of a commercially available source of freeze-dried plasma a top priority.

In April 2014, Vascular Solutions entered into a Cooperative Research and Development Program with USAMMDA. Under the CRADA, USAMMDA provides funding for the regulatory and clinical work, and Vascular Solutions owns all intellectual property and commercial rights to the product.

Under the terms of the collaboration agreement, Vascular Solutions is responsible for product development and establishing manufacturing operations, including chemistry, manufacturing, and controls information to support the submission of the Investigational New Drug application, which was made in October of 2016.

USAMMDA is responsible for sponsoring, managing, and funding all preclinical and clinical studies required to support a Biologic License Application for commercialization.

Following the FDA review process, Teleflex will be responsible for all post-licensure production, regulatory, and commercial marketing and distribution of RePlas Freeze-Dried Plasma.

Teleflex will be entitled to market RePlas Freeze-Dried Plasma, including sales to branches of the military and private sector medical providers.

The only licensed forms of plasma currently available in the United States are fresh frozen plasma, plasma frozen within 24 hours after phlebotomy and liquid plasma.

According to the most recent annual Blood Collection, Utilization, and Patient Blood Management Survey Report published by the American Association of Blood Banks, the US blood banking system distributed 3.5m units of plasma to hospitals, clinics, and other providers of medical care during 2013.

Due to the difficulty of using current forms of plasma in remote locations such as in theater medical facilities and battlefield situations, USAMMDA has sought the development of a stable, durably-packaged freeze-dried plasma product that can be easily stored, transported, and administered in remote conditions.

Teleflex is the home of Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, and Weck trusted brands.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 16, 2017
Words:469
Previous Article:Voisin Consulting Life Sciences appoints Carole Jones as director of market access.
Next Article:Healthcare, Life Sciences IT Firm Emids Opens London Office.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters